ImmunOs Therapeutics AG leverages its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases. The Company´s lead product candidate has the potential to treat multiple types of solid tumors and hematologic malignancies by targeting multiple components of the immune system to activate profound anti-tumor responses. ImmunOs is also developing antibodies to block the activation of specific HLA protein molecules associated with autoimmune diseases.